Niklas Klümper

Niklas Klümper: Trastuzumab deruxtecan achieving high ORR in patients with advanced HER2-amplified solid tumors

Niklas Klümper, Senior Consultant for Urology and GU Oncology at University Hospital Bonn, shared a post on X:

“New data shows T-DXd achieving high ORR with durable response in patients with advanced HER2-amplified solid tumors, as determined by cfDNA testing!

A strong example of an elegant biomarker-based basket design, further supporting tumor-agnostic approval of T-DXd for HER2-positive cancers.”

Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial.

Authors: Masataka Yagisawa, Hiroya Taniguchi, Taroh Satoh, Shigenori Kadowaki, Yu Sunakawa, Tomohiro Nishina, Yoshito Komatsu, Taito Esaki, Daisuke Sakai, Ayako Doi, Takeshi Kajiwara, Hiromi Ono, Masatoshi Asano, Nami Hirano, Justin Odegaard, Satoshi Fujii, Shogo Nomura, Hideaki Bando, Akihiro Sato, Takayuki Yoshino, Yoshiaki Nakamura

Niklas Klümper

Akihiro Sato Ayako Doi cancer cfDNA testing Daisuke Sakai HER2-positive cancers Hideaki Bando Hiromi Ono Hiroya Taniguchi Justin Odegaard Masataka Yagisawa Masatoshi Asano Nami Hirano Niklas Klümper OncoDaily Oncology Satoshi Fujii Shigenori Kadowaki Shogo Nomura solid tumors Taito Esaki Takayuki Yoshino Takeshi Kajiwara Taroh Satoh Tomohiro Nishina Trastuzumab deruxtecan Yoshiaki Nakamura Yoshito Komatsu Yu Sunakawa